Profile of CZECH AF 2012. Profile of atrial fibrillation patients receiving antithrombotic therapy

Jindřich Špinar, Jiří Vítovec, Lenka Špinarová, Viktor Musil

Cor Vasa 2014, 56(3):e207-e216 | DOI: 10.1016/j.crvasa.2014.04.001  

The profile of Czech AF 2012 is an epidemiological survey conducted by 197 Czech internal medicine and cardiology specialists who aimed to provide a comprehensive view of patients with non-valvular atrial fibrillation and their treatment in the Czech Republic. Each specialist had to include 5 consecutive patients.It involved 982 patients with an average age of 69.9 ± 10.04 years. The population of men was slightly higher (n = 543, 55.3%), especially in the under 65 years age group; women were the majority in the age group above 75 years (44.3% of men, 55.7% of women).One quarter (25.1%) of patients were diagnosed with atrial fibrillation...

Impact of patient-related and treatment-related factors on in-hospital mortality of patients with ST-elevation myocardial infarction: Data of Russian Acute Coronary Syndrome Registry

Olga M. Posnenkova, Anton R. Kiselev, Yulia V. Popova, Vladimir I. Gridnev, Mikhail D. Prokhorov, Pavel Ya. Dovgalevsky

Cor Vasa 2014, 56(3):e217-e227 | DOI: 10.1016/j.crvasa.2014.03.004  

Objective: We examined relationships between inpatient medical treatment, reperfusion therapy and in-hospital mortality among patients with ST-elevation myocardial infarction (STEMI) in Russia.Methods: Clinical information about 25,682 patients with STEMI enrolled in the 2010-2011 registry was included retrospectively in the study. Performance of the key guideline-recommended treatment interventions was assessed. Timeliness of reperfusion therapy was evaluated with the help of the following ACC/AHA clinical measures (2008): Time to fibrinolytic therapy, Time to primary percutaneous coronary intervention (PCI) and Reperfusion therapy. Multivariate...

Technical and safety aspects of renal denervation

Karol Čurila, Ján Rosa, Petr Toušek, Jiří Widimský jr., Petr Widimský

Cor Vasa 2014, 56(3):e228-e234 | DOI: 10.1016/j.crvasa.2014.02.004  

Aims: Renal denervation is a novel method used to treat patients with resistant hypertension. Several studies showing the efficacy of this method in blood pressure reduction have been published. However, there is a lack of data that focused on the technical aspects of the procedure. The aim of this paper is to present and discuss the technical and safety issues of the procedure.Methods and results: 37 patients underwent renal denervation using a Symplicity catheter between 10/2011 and 8/2013. Number of ablations, procedural time, consumption of contrast agent and complication rate during hospitalization were recorded. Bilateral denervation was...

Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: Rationale and design of a multicenter randomized study-PRAGUE-15

Petr Toušek, Jiří Widimský jr., Ján Rosa, Karol Čurila, Marian Branny, Igor Nykl, Miloš Táborský, Jan Václavík, Petr Widimský

Cor Vasa 2014, 56(3):e235-e239 | DOI: 10.1016/j.crvasa.2014.04.004  

Catheter-based renal denervation (RDN) was considered as a promising method for treatment of resistant hypertension and was increasingly being used worldwide. However, there are equivocal results from only two randomized trials studying the effect of such intervention. Thus, additional data from properly designed long-term comparative trials are needed. The PRAGUE-15 trial is designed as an open, prospective, randomized multicenter trial comparing RDN versus intensified medical treatment in patients with resistant hypertension. Patients randomized to the medical treatment group will receive spironolactone in the absence of contraindications. The primary...

Midterm patency and risk factors for vein graft occlusion after endoscopic harvest

Vojtěch Kurfirst, Júlia Čanádyová, Jiří Kubále, Petr Lhoták, Aleš Mokráček

Cor Vasa 2014, 56(3):e240-e245 | DOI: 10.1016/j.crvasa.2014.04.006  

Objectives: To evaluate midterm patency of saphenous vein grafts harvested endoscopically and identify risk factors for subsequent vein graft occlusion.Methods: Fifty consecutive patients undergoing coronary artery bypass surgery with venous graft harvested by endoscopic method were included in the study. Patients underwent computed tomography angiography follow--up at mean 24 months. Multivariate logistic regression was used to analyze associations between preoperative variables (age, ejection fraction, body mass index, gender, hyperlipidemia, hypertension, diabetes mellitus, smoking, number of defects per graft and target vessel stenosis) and...

Dual antiplatelet therapy in patients with acute coronary syndrome treated by surgical revascularization

Jiří Pařenica, Petr Němec

Cor Vasa 2014, 56(3):e246-e253 | DOI: 10.1016/j.crvasa.2014.04.005  

Twelve-month dual antiplatelet therapy (DAPT) based on a combination of acetylsalicylic acid and purine receptor P2Y12 inhibitor is a standard for all patients with acute coronary syndrome (unstable angina pectoris, NSTEMI and STEMI). Previous sub-analysis of CURE and ACUITY studies suggested that DAPT could bring benefit even for patients treated by surgical revascularization. Sub-analysis of PLATO trial conducted on 1261 patients who underwent surgical revascularization within 12 months demonstrated a reduction of cardiovascular and total mortality within a group of patients treated with ticagrelor and acetylsalicylic acid compared to patients treated...

The WOEST study: Critical considerations and applicability

Andrea Rubboli, Raffaele De Caterina

Cor Vasa 2014, 56(3):e254-e258 | DOI: 10.1016/j.crvasa.2014.03.001  

Triple therapy (TT) with a vitamin K-antagonist (VKA), aspirin, and clopidogrel is currently recommended as the optimal antithrombotic therapy for patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention with stent implantation (PCI-S). While appearing highly effective for preventing the combined incidence of death, myocardial infarction, repeat revascularization, stent thrombosis, and stroke, TT is associated with a high incidence of bleeding. In the recent What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST) study, dual therapy (DT)...

Summary of the 2013 ESC guidelines on the management of stable coronary artery disease. Prepared by the Czech Society of Cardiology

Michael Želízko, František Toušek, Hana Skalická

Cor Vasa 2014, 56(3):e259-e273 | DOI: 10.1016/j.crvasa.2014.02.006  

Rare myxoid liposarcoma metastasis to the interventricular septum of the heart

Renata Virtová, Tomáš Gazdič, Jan Pirk, Radka Kočková, Otakar Bělohlávek, Kateřina Kamarádová, Kateřina Kubáčková, Dana Kautznerová, Jan Vydra, Josef Kautzner

Cor Vasa 2014, 56(3):e274-e278 | DOI: 10.1016/j.crvasa.2013.07.004  

Liposarcomas are malignant tumors of the soft tissue. Myxoid liposarcoma is the second most common subtype of these tumors in adults. It accounts for approximately 20% of all malignant soft tissue tumors [1,2]. Peak of its incidence occurs between 40 and 60 years of age with relatively indolent clinical course (Matsumoto et al. [2007] [3], Cho et al. [2010] [4], Fairman et al. [2005] [5]). Typical localizations of myxoid liposarcoma comprise limbs, particularly thighs with a tendency to metastasize into extrapulmonary sites such as retroperitoneum, mediastinum, bones. Cardiac metastases are extremely rare.We present a case of a 36-year-old man...

Cor et Vasa. Osobní dopis předsedy ČKS všem vědecky (publikačně) aktivním členům společnosti

Petr Widimský

Cor Vasa 2014, 56(3):335  

Aktuální otázky protidestičkové léčby

MUDr. Zuzana Zafarová

Cor Vasa 2014, 56(3):342-344 | DOI: 10.33678/cor.2014.020  

Komplexní prevence cévních mozkových příhod u pacientů s fibrilací síní

Cor Vasa 2014, 56(3):345-348 | DOI: 10.33678/cor.2014.021  

Nová antikoagulancia u fibrilace síní - kdo vítězí?

MUDr. Zuzana Zafarová

Cor Vasa 2014, 56(3):349-351 | DOI: 10.33678/cor.2014.022  

Trandolapril je vhodnou volbou u hypertoniků s metabolickým syndromem či s rizikem rozvoje diabetu a u pacientů se srdečním selháním po infarktu myokardu

MUDr. Zuzana Zafarová

Cor Vasa 2014, 56(3):353-355 | DOI: 10.33678/cor.2014.023  

Rivaroxaban přináší výhody u pacientů s fibrilací síní i v prevenci a léčbě hluboké žilní trombózy a plicní embolie

Cor Vasa 2014, 56(3):357-358 | DOI: 10.33678/cor.2014.024  

Posouváme hranice kardiovaskulární prevence dál - první fixní trojkombinace antihypertenziv perindopril + amlodipin + indapamid v boji proti neuspokojivé kompenzaci hypertenze a reziduálnímu kardiovaskulárnímu riziku

MUDr. Zuzana Zafarová

Cor Vasa 2014, 56(3):359-361 | DOI: 10.33678/cor.2014.025  

Zápis ze schůze výboru ČKS konané 27. 11. 2013 v hotelu Diplomat Praha

P. Widimský, P. Riebauerová

Cor Vasa 2014, 56(3):365-366  

Zápis ze schůze výboru ČKS konané 4. 2. 2014 v kanceláři ČKS v Brně

P. Widimský, P. Riebauerová

Cor Vasa 2014, 56(3):367-368  

Jiří Widimský a kolektiv: Srdeční selhání

Prof. MUDr. Vladimír Staněk, CSc.

Cor Vasa 2014, 56(3):341  

Zkušenosti s implantabilními kardiovertery-defibrilátory u dětí do deseti let věku v Dětském kardiocentru

Jana Hojerová, Olga Spurná, Peter Kubuš

Cor Vasa 2014, 56(3):362-364  

Životní výročí pana profesora MUDr. Jiřího Kvasničky, CSc.

Michael Aschermann

Cor Vasa 2014, 56(3):336-337  

Profesorka Hana Rosolová slaví významné životní jubileum

Jan Filipovský, Michael Aschermann

Cor Vasa 2014, 56(3):338-339  

Významné životní výročí (70 let) prof. MUDr. Jana Dominika, CSc.

Jan Harrer

Cor Vasa 2014, 56(3):340-341  

Editorial Board

Editorial board

Cor Vasa 2014, 56(3):i | DOI: 10.1016/S0010-8650(14)00052-6